Vito Di Marco
Vito Di Marco
Verified email at
Cited by
Cited by
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C
S Petta, C Cammā, C Scazzone, C Tripodo, V Di Marco, A Bono, D Cabibi, ...
Hepatology 51 (4), 1158-1167, 2010
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
P Dongiovanni, S Petta, C Maglio, AL Fracanzani, R Pipitone, E Mozzi, ...
Hepatology 61 (2), 506-514, 2015
Field‐practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy
M Iavarone, G Cabibbo, F Piscaglia, C Zavaglia, A Grieco, E Villa, ...
Hepatology 54 (6), 2055-2063, 2011
The long‐term course of chronic hepatitis B
V Di Marco, OL Iacono, C Cammā, A Vaccaro, M Giunta, G Martorana, ...
Hepatology 30 (1), 257-264, 1999
Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine
DV Di Marco, A Marzano, P Lampertico, P Andreone, T Santantonio, ...
Hepatology 40 (4), 883-891, 2004
Prophylaxis and treatment of hepatitis B in immunocompromised patients
A Marzano, E Angelucci, P Andreone, M Brunetto, R Bruno, P Burra, ...
Digestive and Liver Disease 39 (5), 397-408, 2007
Hepatitis C viremia in chronic liver disease: relationship to interferon‐α or corticosteroid treatment
S Magrin, A Craxi, C Fabiano, RG Simonetti, G Fiorentino, L Marino, ...
Hepatology 19 (2), 273-279, 1994
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C
L Rizzo, V Calvaruso, B Cacopardo, N Alessi, M Attanasio, S Petta, ...
American Journal of Gastroenterology 106 (12), 2112-2120, 2011
SAFE biopsy: a validated method for large‐scale staging of liver fibrosis in chronic hepatitis C
G Sebastiani, P Halfon, L Castera, S Pol, DL Thomas, A Mangia, ...
Hepatology 49 (6), 1821-1827, 2009
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C
C Camma, S Bruno, V Di Marco, D Di Bona, M Rumi, M Vinci, C Rebucci, ...
Hepatology 43 (1), 64-71, 2006
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
AJ van der Meer, JJ Feld, H Hofer, PL Almasio, V Calvaruso, ...
Journal of hepatology 66 (3), 485-493, 2017
Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection
S Petta, C Camma, V Di Marco, N Alessi, D Cabibi, R Caldarella, A Licata, ...
American Journal of Gastroenterology 103 (5), 1136-1144, 2008
Interferon‐α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response
L Pagliaro, A Craxí, C Cammaá, F Tiné, V Di Marco, OL Iacono, P Almasio
Hepatology 19 (4), 820-828, 1994
Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents
V Calvaruso, G Cabibbo, I Cacciola, S Petta, S Madonia, A Bellia, F Tinč, ...
Gastroenterology 155 (2), 411-421. e4, 2018
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease
S Petta, M Maida, FS Macaluso, V Di Marco, C Camma, D Cabibi, A Craxė
Hepatology 62 (4), 1101-1110, 2015
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation …
S Petta, VWS Wong, C Cammā, JB Hiriart, GLH Wong, F Marra, J Vergniol, ...
Hepatology 65 (4), 1145-1155, 2017
Cost‐effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
C Cammā, S Petta, M Enea, R Bruno, F Bronte, V Capursi, A Cicchetti, ...
Hepatology 56 (3), 850-860, 2012
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
P Caraceni, O Riggio, P Angeli, C Alessandria, S Neri, FG Foschi, ...
The Lancet 391 (10138), 2417-2429, 2018
Hyperuricemia is associated with histological liver damage in patients with non‐alcoholic fatty liver disease
S Petta, C Cammā, D Cabibi, V Di Marco, A Craxė
Alimentary pharmacology & therapeutics 34 (7), 757-766, 2011
Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index
S Petta, V Di Marco, C Cammā, G Butera, D Cabibi, A Craxi
Alimentary pharmacology & therapeutics 33 (12), 1350-1360, 2011
The system can't perform the operation now. Try again later.
Articles 1–20